Oncology

Latest News

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com
New Developments Warrant Rethinking HCC Transplant Criteria

April 29th 2025

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Women with fatigue | Image credit: Adobe Stock
Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

April 29th 2025

senior scientist | Image credit: Ohio State University
Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

April 28th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
October 17th 2014

Roche Joins the Immuno-oncology Front With a PD-L1 inhibitor

While the current approved immuno-oncolgy drugs have been approved for melanoma, Roche has also been evaluating their new molecule in triple-negative breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium.
Site Logo
October 16th 2014

Exciting Clinical Results With Novartis' Leukemia Immune Therapy

The regimen, based on reprogramming the patient's immune T cells to attack the cancer cells, led to the disappearance of cancer in 90 percent of patients, according to a study published in the New England Journal of Medicine.
Site Logo
October 15th 2014

After Roche, Celgene Faces Value Push-Back From NICE

After Roche saw 2 product rejects a few weeks back from NICE, based on a value argument, Celgene is in a similar boat with it's multiple myeloma drug pomalidomide.
Site Logo
October 14th 2014

Study Identifies Gender Bias in HPV Vaccination

Fewer than 15% of physicians routinely recommend HPV vaccination to male patients, according to the study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
Site Logo
October 14th 2014

ASCO Endorses CAP/IASLC/AMP Guideline on Molecular Testing for Lung Cancer

The American Society of Clinical Oncology has endorsed the joint guidelines established by the 3 Associations to help physicians make evidence-based decisions when selecting patients to administer some of the targeted therapies developed for lung cancer.
Site Logo
October 13th 2014

Transition to Managed Care Proves Rough for Ohio Dual Eligibles, Reports Say

Mary K. Caffrey
Ohio is the latest state to experience a rough transition to managed care in its Medicaid program, according to weekend reports. Delayed payments and service disruptions to fragile patients are among the complaints. Kentucky had a similar bumpy start when it changed to Medicaid managed care in 2011, and Kansas has had many problems recently.
Site Logo
October 13th 2014

BMS' PD-1 Inhibitor, Nivolumab, to be Evaluated With Jansenn's Ibrutinib in NHL

Opdivo (nivolumab), which was approved in Japan in July 2014, is being globally developed for evaluation in non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), head and neck cancer, glioblastoma, as well as NHL.
Site Logo
October 13th 2014

Priority Review for Pfizer's Palbociclib in Patients with Advanced Breast Cancer

The NDA submitted by Pfizer requests approval of palbociclib as a first-line therapy in combination with letrozole for ER+, HER2- advanced breast cancer.
Site Logo
October 11th 2014

Immuno-oncology Innovation From Amgen Set for Priority Review

The new BiTE antibody technology developed by the company can simultaneously engage 2 different targets, which can help recruit T-cells to malignant cells, and will be evaluated in ALL patients.
Site Logo
October 11th 2014

FDA Approves Akynzeo for Chemotherapy-Associated Nausea and Vomiting

The approval follows 2 clinical trials evaluating the regimen in 1720 cancer patients receiving chemotherapy.
Site Logo
October 10th 2014

Velcade Approved For Treatment-Naïve Mantle Cell Lymphoma Patients

The approval extends the use of bortezomib beyond relapsed and refractory patients.
Site Logo
October 9th 2014

Urine Test Could Diagnose Prostate Cancer

The identification of specific RNA molecules in the urine of individuals with prostate cancer raises hope for a non-invasive test for the disease.
Site Logo
October 8th 2014

Genentech Faces Backlash Following Onco-Specialty Decision

Having decided to restrict the distribution of 3 of its top-selling oncology medications, Avastin, Rituxan, and Herceptin only through specialty pharmacies, Genentech is witnessing protests in various forms from healthcare centers.
Episode 17 - Final Thoughts on the State of Medical Oncology
October 8th 2014

Episode 17 - Final Thoughts on the State of Medical Oncology

Episode 16 - Impact of Electronic Medical Records in Oncology Practices
October 8th 2014

Episode 16 - Impact of Electronic Medical Records in Oncology Practices

Episode 15 - Quality Metrics and Patient-Reported Outcomes
October 8th 2014

Episode 15 - Quality Metrics and Patient-Reported Outcomes

Episode 14 - Quality Initiatives in Medical Oncology
October 8th 2014

Episode 14 - Quality Initiatives in Medical Oncology

Episode 13 - Patient-Centered Approach to Improve Quality
October 8th 2014

Episode 13 - Patient-Centered Approach to Improve Quality

Episode 12 - Cost Considerations and Comparative Effectiveness Research
October 8th 2014

Episode 12 - Cost Considerations and Comparative Effectiveness Research

Episode 11 - The Importance of Patient Education
October 8th 2014

Episode 11 - The Importance of Patient Education

Episode 10 - Comparative Effectiveness Research
October 8th 2014

Episode 10 - Comparative Effectiveness Research

Episode 9 - Analyzing Incentive Programs
October 8th 2014

Episode 9 - Analyzing Incentive Programs

Episode 8 - Immunotherapy and Pathways: Safety Considerations
October 8th 2014

Episode 8 - Immunotherapy and Pathways: Safety Considerations

Episode 7 - Inclusion of Generic Drugs in Pathways
October 8th 2014

Episode 7 - Inclusion of Generic Drugs in Pathways

Episode 6 - Measuring the Success of Clinical Pathways
October 8th 2014

Episode 6 - Measuring the Success of Clinical Pathways

Episode 5 - Utilization of Clinical Pathways in Oncology
October 8th 2014

Episode 5 - Utilization of Clinical Pathways in Oncology

Episode 4 - Potential Impact of Data Integration Projects
October 8th 2014

Episode 4 - Potential Impact of Data Integration Projects

Episode 3 - Examining Data Integration Platforms
October 8th 2014

Episode 3 - Examining Data Integration Platforms

Episode 2 - Gaps in Data Exchange From a Payer Perspective
October 8th 2014

Episode 2 - Gaps in Data Exchange From a Payer Perspective

Episode 1 - Evidence-Based Decisions for Data Generation, Collection, and Analysis
October 8th 2014

Episode 1 - Evidence-Based Decisions for Data Generation, Collection, and Analysis

<1
...
148149150151152153154155156
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo